Results 81 to 90 of about 20,955 (176)

Feasibility of a Multimodal Lifestyle Intervention Programme for Patients With Ulcerative Colitis: A Single‐Arm Pilot Study

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
ABSTRACT Introduction Although individual lifestyle interventions have shown promise in improving well‐being in patients with ulcerative colitis (UC), the feasibility of a multimodal approach remains unclear. This study assessed the feasibility of a multimodal lifestyle intervention programme.
Dorien Oomkens   +7 more
wiley   +1 more source

Budesonide for the Treatment of Inflammatory Bowel Disease

open access: yesCanadian Journal of Gastroenterology, 1994
While corticosteroids are the most effective treatment for the symptomatic management of patients with inflammatory bowel disease (IBD), they cause serious side effects.
Gordon R Greenberg
doaj   +1 more source

Plasma Interleukin‐10 Levels and IL10 Genetic Variants Are Associated With Clinical Outcomes in Patients With Severe COVID‐19 Treated With Corticosteroids

open access: yesJournal of Medical Virology, Volume 98, Issue 11, November 2026.
ABSTRACT We aimed to evaluate the association between IL10 variants and plasma IL‐10 levels and clinical outcomes in patients with severe COVID‐19 treated with corticosteroids. We studied 944 patients with severe COVID‐19 who were treated with corticosteroids.
Ingrid Fricke‐Galindo   +12 more
wiley   +1 more source

Right Angle, Wrong Assumptions: A Case of Endobronchial Mucormycosis Presenting as a Pedunculated Mass Mimicking Malignancy

open access: yesRespirology Case Reports, Volume 14, Issue 11, November 2026.
We report a case of endobronchial pulmonary mucormycosis presenting as a pedunculated endobronchial mass in a patient with poorly controlled Type 2 diabetes mellitus and chronic obstructive pulmonary disease. The lesion was initially suspected to be lung cancer, highlighting the importance of considering mucormycosis in the differential diagnosis of an
Rabbia Abbas   +6 more
wiley   +1 more source

Cost-effectiveness of as-needed budesonide-formoterol in adults with mild asthma: the Novel START trial

open access: yesERJ Open Research
Background The Global Initiative for Asthma recommends as-needed combination inhaled corticosteroid-formoterol reliever for mild asthma. Its cost-effectiveness is uncertain outside double-blind regulatory trials.
William Leung   +13 more
doaj   +1 more source

Symmetrical Drug‐Related Intertriginous and Flexural Exanthema (SDRIFE) due to Dexamethasone Used as Oncologic Premedication

open access: yes
Contact Dermatitis, EarlyView.
Tommaso Galeotti   +5 more
wiley   +1 more source

Prospective Study of Targeted Busulfan–Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1369-1377, November 2026.
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim   +6 more
wiley   +1 more source

Comparison of the Consequences of Intratracheal Administration of Surfactant Plus Budesonide with Surfactant alone in Preterm Infants with Respiratory Distress Syndrome [PDF]

open access: yesمجله علمی دانشگاه علوم پزشکی کردستان
Background and Aim: To control complications in infants with respiratory distress syndrome, surfactants and auxiliary drugs such as budesonide are used to reduce the inflammatory reactions of the airways. The aim of this study is to compare the effect of
Morteza Habibi, Fatemeh Toohidinia
doaj  

Occupational Allergic Contact Dermatitis due to Tixocortol Pivalate in a Manufacture Worker

open access: yes
Contact Dermatitis, EarlyView.
Aurore Grandjean   +3 more
wiley   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1819-1830, November 2026.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy